• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

    11/13/24 9:24:55 PM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    SC 13D/A 1 d877238dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Oscar Health, Inc.

    (Name of Issuer)

    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

    687793109

    (CUSIP Number)

    Jed Feldman

    c/o Thrive Capital, 295 Lafayette Street, 7th Fl.

    New York, NY 10012

    646-680-0240

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 11, 2024

    (Date of Event Which Requires Filing of Statement on Schedule 13D)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), checking the following box. ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     (1)   

     Name of Reporting Persons:

     

     Thrive Capital Partners II, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     6,103,319(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     6,103,319(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     6,103,319(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     2.8%(2)(*)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN

     

    (1)

    Consists of Class B common stock, par value $0.00001 per share (“Class B Common Stock”), of the Issuer. The rights of the holders of Class A common stock, par value $0.00001 per share (“Class A Common Stock”), and Class B Common Stock are identical, except with respect to voting, conversion and transfer rights. Each share of Class A Common Stock is entitled to one vote per share. Each share of Class B Common Stock is entitled to 20 votes per share and is convertible at the election of the holder into one share of Class A Common Stock. In addition, each share of Class B Common Stock will be automatically converted into one share of Class A Common Stock on the date that is seven years from the date of the prospectus used in connection with the Issuer’s initial public offering or upon the occurrence of certain events as set forth in the Issuer’s certificate of incorporation.

    (2)

    Pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the percent of class was calculated based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q as filed by the Issuer with the SEC on November 7, 2024, and (ii) the shares of Class B Common Stock of the Issuer beneficially owned by the reporting person (with such shares treated as converted into shares of Class A Common Stock only for purposes of computing the percentage ownership of the reporting person pursuant to the Exchange Act).

    (*)

    This Schedule 13D reflects certain additional purchases made by the Thrive Capital Funds (as defined herein). Notwithstanding these purchases, note that in certain places our percentage of a given class decreased only because the number of shares of Oscar’s Class A Common Stock has increased since our last Schedule 13D filed on January 27, 2022.


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners II GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     6,103,319(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     6,103,319(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     6,103,319(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     2.8%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Thrive Capital Partners III, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     22,391,068(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     22,391,068(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     22,391,068(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     9.6%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Claremount TW, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     757,239(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     757,239(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     757,239(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     0.4%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners III GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     23,148,307(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     23,148,307(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     23,148,307(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     9.9%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Thrive Capital Partners V, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     1,040,704(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     1,040,704(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     1,040,704(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     0.5%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Claremount V Associates, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     19,239(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     19,239(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     19,239(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     <0.1%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners V GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     1,059,943(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     1,059,943(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     1,059,943(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     0.5%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Thrive Capital Partners VI Growth, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     2,498,513(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     2,498,513(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     2,498,513(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     1.2%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Claremount VI Associates, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     48,982(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     48,982(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     48,982(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     <0.1%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners VI GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     2,547,495(1)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     2,547,495(1)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     2,547,495(1)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     1.2%(2)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Thrive Capital Partners VII Growth, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     9,897,434(3)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     9,897,434(3)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     9,897,434(3)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     4.6%(4)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN

     

    (3)

    Consists of shares of Class A Common Stock, including 4,155,911 shares of Class A Common Stock issuable upon conversion of the outstanding principal of Convertible Notes (the “Note Shares”) at the current Conversion Rate (as defined in the Indenture), to the extent that such Note Shares would be deemed to be beneficially owned by the reporting person for purposes of Rule 13d-3 of the Exchange Act.

    (4)

    Pursuant to Rule 13d-3 of the Exchange Act, the percent of class was calculated based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q as filed by the Issuer with the SEC on November 7, 2024, and (ii) the shares of Class A Common Stock underlying Convertible Notes beneficially owned by the reporting person (with such shares treated as converted into shares of Class A Common Stock only for purposes of computing the percentage ownership of the reporting person pursuant to the Exchange Act).


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners VII Growth GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     9,897,434(3)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     9,897,434(3)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     9,897,434(3)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     4.6%(4)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Claremount VII Associates, L.P.

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     WC

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     119,288(5)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     119,288(5)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     119,288(5)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     0.1%(4)

    (14)   

     Type of Reporting Person (See Instructions):

     

     PN

     

    (5)

    Consists of shares of Class A Common Stock, including 50,111 shares of Class A Common Stock issuable upon conversion of the outstanding principal of Convertible Notes at the current Conversion Rate (as defined in the Indenture), to the extent that such Note Shares would be deemed to be beneficially owned by the reporting person for purposes of Rule 13d-3 of the Exchange Act.


     (1)   

     Name of Reporting Persons:

     

     Thrive Partners VII GP, LLC

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     119,288(5)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     119,288(5)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     119,288(5)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     0.1%(4)

    (14)   

     Type of Reporting Person (See Instructions):

     

     OO


     (1)   

     Name of Reporting Persons:

     

     Joshua Kushner

     (2)   

     Check the Appropriate Box if a Member of a Group (See Instructions):

     (a) ☐  (b) ☒

     

     (3)   

     SEC Use Only:

     

     (4)   

     Source of Funds (See Instructions):

     

     AF

     (5)   

     Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

     ☐

     (6)   

     Citizenship or Place of Organization:

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)     

     Sole Voting Power

     

     42,875,786(6)

      (8)     

     Shared Voting Power

     

      (9)     

     Sole Dispositive Power

     

     42,875,786(6)

       (10)     

     Shared Dispositive Power

     

    (11)   

     Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     42,875,786(6)

    (12)   

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

     ☐

    (13)   

     Percent of Class Represented by Amount in Row (11):

     

     17.2%(7)

    (14)   

     Type of Reporting Person (See Instructions):

     

     IN

     

    (6)

    Consists of 5,810,700 shares of Class A Common Stock, 32,859,064 shares of Class B Common Stock, and 4,206,022 shares of Class A Common Stock issuable upon conversion of the outstanding principal of Convertible Notes at the current Conversion Rate (as defined in the Indenture), to the extent that such Note Shares would be deemed to be beneficially owned by the reporting person for purposes of Rule 13d-3 of the Exchange Act. The rights of the holders of Class A Common Stock and Class B Common Stock are identical, except with respect to voting, conversion and transfer rights. Each share of Class A Common Stock is entitled to one vote per share. Each share of Class B Common Stock is entitled to 20 votes per share and is convertible into one share of Class A Common Stock.

    (7)

    Pursuant to Rule 13d-3 of the Exchange Act, the percent of class was calculated based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q as filed by the Issuer with the SEC on November 7, 2024, (ii) the shares of Class A Common Stock underlying Convertible Notes beneficially owned by the reporting person and (iii) the shares of Class B Common Stock beneficially owned by the reporting person (with such shares treated as converted into shares of Class A Common Stock only for purposes of computing the percentage ownership of the reporting person pursuant to the Exchange Act).


    ITEM 1. SECURITY AND ISSUER

    This Amendment No. 3 (this “Amendment”) amends and supplements the Schedule 13D (the “Schedule 13D”) filed by the Reporting Persons on August 30, 2021, as amended, with respect to the Class A common stock, $0.00001 par value per share (the “Class A Common Stock”), of Oscar Health, Inc. (the “Company” or the “Issuer”). The Issuer also has Class B common stock, $0.00001 par value per share (the “Class B Common Stock” and together with the Class A Common Stock, the “Common Stock”), issued and outstanding, which stock is convertible on a one-for-one basis into shares of Class A Common Stock at the election of the holder and automatically upon the occurrence of certain events described in the Issuer’s certificate of incorporation. The address of the principal executive offices of the Issuer is 75 Varick Street, 5th Floor, New York, NY, 10013.

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

    Item 3 of the Schedule 13D is hereby amended and restated as follows:

    The Thrive Capital Funds purchased the shares of Common Stock set forth in Item 5 for an aggregate of approximately $187,582,285, using funds from working capital. In addition, on January 27, 2022, pursuant to the Investment Agreement previously described in Item 6 of this statement, the Company agreed to issue and sell to Thrive Capital Partners VII Growth, L.P. (“Thrive VII Growth”) and Claremount VII Associates, L.P. (“Claremount VII”), and Thrive VII Growth and Claremount VII agreed to purchase, $35,000,000 in the aggregate principal amount of the Company’s 7.25% Convertible Senior Notes due 2031 (the “Convertible Notes” or “Notes”) using funds from working capital.

    The information set forth in Item 4 and Item 5(c) below is incorporated by reference in its entirety into this Item 3.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

    (a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. Pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the percent of class was calculated based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q as filed by the Issuer with the SEC on November 7, 2024, (ii) the shares, if any, of Class A Common Stock underlying Convertible Notes beneficially owned by the reporting person and (iii) the shares, if any, of Class B Common Stock of the Issuer beneficially owned by the reporting person (with such shares treated as converted into shares of Class A Common Stock only for purposes of computing the percentage ownership of the reporting person pursuant to the Exchange Act).

    Thrive Capital Partners II, L.P. (“Thrive II”) directly holds 6,103,319 shares of Class B common stock. Thrive Partners II GP, LLC (“Thrive Partners II”), as the general partner of Thrive II, may be deemed to beneficially own the shares directly held Thrive II.

    Thrive Capital Partners III, L.P. (“Thrive III”) directly holds 22,391,068 shares of Class B common stock and Claremount TW, L.P. (“Claremount TW”) directly holds 757,239 shares of Class B common stock. Thrive Partners III GP, LLC (“Thrive Partners III”), as the general partner of Thrive III and Claremount TW, may be deemed to beneficially own the shares directly held Thrive III and Claremount TW.

    Thrive Capital Partners V, L.P. (“Thrive V”) directly holds 1,040,704 shares of Class B common stock and Claremount V Associates, L.P. (“Claremount V”) directly holds 19,239 shares of Class B common stock. Thrive Partners V GP, LLC (“Thrive Partners V”), as the general partner of Thrive V and Claremount V, may be deemed to beneficially own the shares directly held Thrive V and Claremount V.

    Thrive Capital Partners VI Growth, L.P. (“Thrive VI Growth”) directly holds 2,498,513 shares of Class B common stock and Claremount VI Associates, L.P. (“Claremount VI”) directly holds 48,982 shares of Class B common stock. Thrive Partners VI GP, LLC (“Thrive Partners VI”), as the general partner of Thrive VI Growth and Claremount VI, may be deemed to beneficially own the shares directly held Thrive VI Growth and Claremount VI.


    Thrive VII Growth directly holds 5,741,523 shares of Class A common stock and, subject to the terms of conversion applicable to the Convertible Notes set forth in the Indenture, may be deemed to beneficially own 4,155,911 shares of Class A common stock issuable upon conversion of the outstanding principal of Convertible Notes at the current Conversion Rate (as defined in the Indenture). Thrive Partners VII Growth GP, LLC (“Thrive Partners VII Growth”), as the general partner of Thrive VII Growth, may be deemed to beneficially own the shares directly held and/or beneficially owned by Thrive VII Growth.

    Claremount VII (together with Thrive II, Thrive III, Thrive V, Thrive VI Growth, Claremount TW, Claremount V, Claremount VI and Thrive VII Growth, the “Thrive Capital Funds”) directly holds 69,177 shares of Class A common stock and, subject to the terms of conversion applicable to the Convertible Notes set forth in the Indenture, may be deemed to beneficially own 50,111 shares of Class A common stock issuable upon conversion of the outstanding principal of Convertible Notes at the current Conversion Rate (as defined in the Indenture). Thrive Partners VII GP, LLC (“Thrive Partners VII” and together with Thrive Partners II, Thrive Partners III, Thrive Partners V, Thrive Partners VI and Thrive Partners VII Growth, the “Thrive General Partners”), as the general partner of Claremount VII, may be deemed to beneficially own the shares directly held and/or beneficially owned by Claremount VII.

    As the sole managing member of each of the Thrive General Partners, Mr. Kushner may be deemed to beneficially own the Shares held and/or beneficially owned by the Thrive Capital Funds.

    (c) Information concerning transactions in the shares of Common Stock effected within the last 60 days by the Reporting Persons is set forth in Annex I of this Schedule 13D.

    (d) Except as described herein, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities covered by this statement.

    (e) Not applicable


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    Dated: November 13, 2024

     

    Thrive Capital Partners II, L.P.
    By: Thrive Partners II GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Capital Partners III, L.P.
    By: Thrive Partners III GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Capital Partners V, L.P.
    By: Thrive Partners V GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Capital Partners VI Growth, L.P.
    By: Thrive Partners VI GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Capital Partners VII Growth, L.P.
    By: Thrive Partners VII Growth GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Claremount TW, L.P.
    By: Thrive Partners III GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member


    Claremount V Associates, L.P.
    By:   Thrive Partners V GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Claremount VI Associates, L.P.
    By:   Thrive Partners VI GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Claremount VII Associates, L.P.
    By:   Thrive Partners VII GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Partners II GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Partners III GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Partners V GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Partners VI GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member
    Thrive Partners VII Growth GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member


    Thrive Partners VII GP, LLC
    By:  

    /s/ Joshua Kushner

      Name: Joshua Kushner
      Title: Managing Member

    /s/ Joshua Kushner

    Joshua Kushner


    Annex I

    Information With Respect to Transactions of Class A Common Stock during the Past 60 Days

     

    Name

       Date of
    Purchase
        

    Nature of

    Transaction

       Amount of
    Securities
    Purchased
         Average
    Price Per
    Share
        

    Where and How the

    Transaction was

    Effected

    Thrive VII Growth

         11/11/2024      Purchase of Class A Common Stock      272,754      $ 13.5779      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.

    Claremount VII

         11/11/2024      Purchase of Class A Common Stock      3,286      $ 13.5779      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.

    Thrive VII Growth

         11/12/2024      Purchase of Class A Common Stock      415,808      $ 13.6772      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.

    Claremount VII

         11/12/2024      Purchase of Class A Common Stock      5,011      $ 13.6772      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.

    Thrive VII Growth

         11/13/2024      Purchase of Class A Common Stock      354,349      $ 13.7369      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.

    Claremount VII

         11/13/2024      Purchase of Class A Common Stock      4,270      $ 13.7369      Effected on the open market in accordance with the daily volume and other limitations of Rule 10b-18.
    Get the next $OSCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    3/13/2025$20.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/10/2024$12.00Underperform
    Jefferies
    11/6/2024$21.00 → $13.50Neutral → Underperform
    BofA Securities
    10/7/2024$23.00Neutral
    UBS
    6/26/2024$25.00Overweight
    Piper Sandler
    5/30/2024$28.00Outperform
    Robert W. Baird
    5/30/2024$25.00 → $21.00Buy → Neutral
    BofA Securities
    3/22/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

      SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 4:07:27 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Oscar Health Inc.

      SC 13G - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 1:28:35 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

      SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

      11/13/24 9:24:55 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robinson Elbert O. Jr. sold $410,750 worth of shares (25,000 units at $16.43), decreasing direct ownership by 28% to 64,512 units (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      5/14/25 4:20:39 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Plouffe David

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:56 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gassen William

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:43 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Financials

    Live finance-specific insights

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

      Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results

      2/4/25 4:05:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oscar Health downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously

      3/13/25 8:18:37 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Oscar Health with a new price target

      Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00

      12/10/24 7:59:30 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously

      11/6/24 7:54:31 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    SEC Filings

    See more
    • SEC Form 144 filed by Oscar Health Inc.

      144 - Oscar Health, Inc. (0001568651) (Subject)

      5/12/25 4:09:55 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Oscar Health Inc.

      10-Q - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 7:11:20 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 6:24:47 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:33:02 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:29:47 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/18/24 5:02:12 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

      With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin

      3/5/25 2:13:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

      1/26/24 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

      9/6/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

      3/15/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care